Cellular Biomedicine Group to Present at Chinese Biopharmaceutical Association-USA Annual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) will present at the 25th Annual Conference of the Chinese Biopharmaceutical Association-USA on August 30, 2020, from 10:10 a.m. to 10:35 a.m. EDT, discussing "Building a Competitive Cell Therapy Pipeline for Cancer Patients". Dr. Yihong Yao, Chief Scientific Officer, will lead the session focused on Cell and Gene Therapy. This virtual event will be broadcast from Rockville, MD. CBMG is known for developing innovative therapies for cancer and degenerative diseases, conducting clinical trials in China.
Details
News Market Reaction – CBMG
The recorded move for CBMG in the trading session of this news was +1.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SHANGHAI, Aug. 26, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, is scheduled for a presentation at the 25th Annual Conference of the Chinese Biopharmaceutical Association-USA (CBA) to be held online August 29-30, 2020.
Presentation Title: | "Building a Competitive Cell Therapy Pipeline for Cancer Patients" |
Session: | Cell and Gene Therapy |
Speaker: | Dr. Yihong Yao, Chief Scientific Officer, CBMG |
Date: | Sunday, August 30, 2020 |
Time: | 10:10 a.m.to 10:35 a.m. EDT |
Location: | Broadcast virtually from Rockville, MD |
Website: |
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific. These partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) approved the Company's IND application for a Phase II trial for AlloJoin®, CBMG's "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company's IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. The NMPA has also accepted CBMG's dossier for an IND application for clinical trials of anti-BCMA CAR-T. CBMG is included in the broad-market Russell 3000® Index the small-cap Russell 2000® Index and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-present-at-chinese-biopharmaceutical-association-usa-annual-conference-301118884.html
SOURCE Cellular Biomedicine Group
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.